IMPACT OF CYTOKINES ON CHRONIC KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETIC PATIENTS FOLLOWING COVID-19
Article Sidebar
Main Article Content
Abstract
The ongoing COVID-19 pandemic, now entering its third year, is characterized by the widespread transmission of the SARS-CoV-2 virus, which exhibits a high contagiousness, diverse clinical presentations, and significant morbidity and mortality among individuals with underlying risk factors. Pathophysiologically, the disease is associated with a systemic inflammatory response, disturbances in cardiometabolic function, and varying degrees of glucose dysregulation, often manifesting as marked hyperglycemia leading to either new-onset or exacerbation of existing diabetes. Furthermore, beyond the acute phase, patients may experience persistent symptoms collectively termed "Long COVID" or "Post-COVID Syndrome," likely attributable to a prolonged state of low-grade inflammation and dysregulated immune response, lasting for weeks or even months. Despite advancements in understanding COVID-related hyperglycemia and diabetes, challenges remain in accurately predicting, managing, and comprehensively understanding the course of these conditions. Few studies have investigated the association of interleukin 17A, IL 11, TGFβ1, cystatin C, and apolipoprotein B (ApoB) with the progression of diabetic kidney disease (DKD) and the risk of CV.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1. Wei, P. F. (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 7). Chinese Medical Journal, 133, 1087–1095.
2. Linschoten, M., Uijl, A., Schut, A., Jakob, C. E. M., Romao, L. R., Bell, R. M., McFarlane, E., Stecher, M., Zondag, A. G. M., van Iperen, E. P. A., et al. (2021). Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease—A cohort study across sixteen countries. MedRxiv. https://doi.org/10.1101/2021.03.11.21253106
3. Leon-Abarca, J. A., Memon, R. S., Rehan, B., Iftikhar, M., & Chatterjee, A. (2020). The impact of COVID-19 in diabetic kidney disease and chronic kidney disease: A population-based study. Acta Biomedica, 91, 2020161. https://doi.org/10.23750/abm.v91i4.10380
4. Toniolo, A., Cassani, G., Puggioni, A., Rossi, A., Colombo, A., Onodera, T., & Ferrannini, E. (2019). The diabetes pandemic and associated infections. Reviews in Medical Microbiology, 30(1), 1–17. https://doi.org/10.1097/MRM.0000000000000155
5. D′Marco, L., Puchades, M. J., Romero-Parra, M., & Gorriz, J. L. (2020). Diabetic kidney disease and COVID-19: The crash of two pandemics. Frontiers in Medicine, 7, 199. https://doi.org/10.3389/fmed.2020.00199
6. Аликулов, И. Т., Юсупова, М. Ш., Султанова, Ф. Т., & Нарзиев, Н. М. (2025). Изучение особенностей клинического течения заболевания у больных хронической сердечной недостаточностью с дисфункцией почек. World Scientific Research Journal, 36(1), 61-65.
7. World Health Organization. (2021). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int
8. Our World in Data. (2021). Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations
9. Naci, H., Kesselheim, A. S., Røttingen, J. A., Salanti, G., Vandvik, P. O., & Cipriani, A. (2020). Producing and using timely comparative evidence on drugs: Lessons from clinical trials for COVID-19. BMJ, 371, m3869. https://doi.org/10.1136/bmj.m3869
10. D’Marco, L., Puchades, M. J., Romero-Parra, M., & Gorriz, J. L. (2020). Diabetic kidney disease and COVID-19: The crash of two pandemics. Frontiers in Medicine, 7, 199. https://doi.org/10.3389/fmed.2020.00199
11.Najmutdinova D.K., Miraxmedova Kh.T., Khusanov A. M., Khudaybergenova D.Kh., Nurmatov A.Kh/ Clinical and Immunological Characteristics of Patients with Type 2 Diabetes Mellitus Complicated by Chronic Kidney Disease that Underwent COVID-19// American Journal of Medicine and Medical Sciences 2024, DOI: 10.5923/j.ajmms.20241401.04, P-16-23 (14.00.00; №2)
12.Нажмутдинова Д.К., Мирахмедова Х.Т., Худайбергенова Д.Х./ Патогенетические аспекты цитокинового профиля постковидных больных СД 2 типа осложненных диабетической нефропатией// Научно-практический журнал re-health journal. – Выпуск №3, 2023, 84-95б. (14.00.00; №)
13.Нажмутдинова Д.К., Мирахмедова Х.Т., Худайбергенова Д.Х./ COVID-19 билан касалланган қандли диабет 2-тоифа билан оғриган беморларда диабетик нефропатиянинг иммунопатогенетик жиҳатлари // Тошкент тиббиёт академияси ахборотномаси №3, 2024, 23-27б. (14.00.00; №13)
14.Нажмутдинова Д.К., Мирахмедова Х.Т., Худайбергенова Д.Х./Влияние гуморального иммунитета на течение хронической болезни почек у больных cахарным диабетом 2-го типа, перенесших COVID-19// // Тошкент тиббиёт академияси ахборотномаси №3, 2024, 140-142б. (14.00.00; №13)
15.Najmutdinova D.K., Miraxmedova Kh.T., Khudaybergenova D.Kh. / Immunological aspects of kidney damage in post-covid patients with type 2 diabetes mellitus// Annals of clinical discipline Volume 1, Issue 1, 2024, 107-113б. (14.00.00; №)